Janssen Biotech, Inc.

Alastair King

Steven Jacobs

Karyn O'Neil

Ricardo Attar

Michael Diem

Sheri Moores

Kristen Picha

Linus Hyun

Donna Klein

Mark L Anderson

Shalom Goldberg

Anderson Mark

Mark Anderson

Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

EGFR and C-met fibronectin type III domain binding molecules

EGFR and c-Met fibronectin type III domain binding molecules

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Cysteine engineered fibronectin type III domain binding molecules

EGFR and C-Met fibronectin type III domain binding molecules

Growing community of inventors

Lake Saint Louis, MO, United States of America

Alastair King